<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883996</url>
  </required_header>
  <id_info>
    <org_study_id>CP-EXP039-0001</org_study_id>
    <nct_id>NCT04883996</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or Hyperopia</brief_title>
  <official_title>A Phase 1/2, Randomized, Placebo Controlled Crossover Study to Assess the Safety, Pharmacodynamics, and Efficacy of EXP039 Ophthalmic Solution in Participants With Myopia or Hyperopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canyon City Eyecare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nevakar, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canyon City Eyecare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the Safety, Pharmacodynamics, and Efficacy of EXP039 Ophthalmic Solution in&#xD;
      Participants with Myopia or Hyperopia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To characterize the effect of pupillary miosis as achieved with EXP039 1% ophthalmic solution&#xD;
      in terms of mean number of lines (Early Treatment Diabetic Retinopathy Study [ETDRS]) of&#xD;
      improvement from baseline in binocular (both eyes open) mesopic high-contrast uncorrected&#xD;
      distance visual acuity (UDVA) at 1-hour post treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UDVA</measure>
    <time_frame>1 hour</time_frame>
    <description>Mesopic high-contrast uncorrected distance visual acuity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hyperopia</condition>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>EXP039</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At Visit 1, single dose 1 drop of EXP039 1% is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop saline at Visit 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At Visit 1, single dose 1 drop of saline is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop EXP039 1% at Visit 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% EXP039</intervention_name>
    <description>1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),</description>
    <arm_group_label>EXP039</arm_group_label>
    <other_name>Isopto® Carpine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline control</intervention_name>
    <description>Saline</description>
    <arm_group_label>Saline control</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 to ≤80 years&#xD;
&#xD;
          2. Participants must be in good general health, with no significant medical problems&#xD;
             that, in the opinion of the investigator, would preclude participation in the trial,&#xD;
             at Screening and/or before administration of the dose of study drug&#xD;
&#xD;
          3. Low-to-moderate hyperopia (SER of +0.50D to +2.00D) or myopia (SER of -0.50 D to&#xD;
             -4.00D) at Screening&#xD;
&#xD;
          4. Between-eye SER difference of no more than 0.50D&#xD;
&#xD;
          5. Best-corrected distance visual acuity better than or equal to 20/20 in both eyes at&#xD;
             Screening&#xD;
&#xD;
          6. Astigmatism in each eye of less than or equal to 0.75D with manifest refraction at&#xD;
             Screening&#xD;
&#xD;
          7. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at&#xD;
             Screening&#xD;
&#xD;
          8. WOCBP must be non-pregnant and non-lactating, and must use a medically approved,&#xD;
             highly effective contraception method from Screening until study completion, including&#xD;
             the follow up period. Female participants who are in same sex relationships are not&#xD;
             required to use contraception.Males must be surgically sterile (&gt;30 days since&#xD;
             vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a&#xD;
             WOCBP, the participant and his partner must use a medically approved, highly effective&#xD;
             contraceptive method from Screening until study completion, including the follow-up&#xD;
             period.&#xD;
&#xD;
          9. Males must not donate sperm for at least 90 days after the last dose of study drug&#xD;
&#xD;
         10. Participants must have the ability and willingness to attend the necessary visits&#xD;
&#xD;
         11. Participants must be willing and able to provide written informed consent after the&#xD;
             nature of the study has been explained and prior to the commencement of any study&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any central corneal abnormality (e.g., keratoconus, Pellucid marginal degeneration,&#xD;
             corneal scar, Fuchs' endothelial dystrophy, guttata, or edema) in either eye that is&#xD;
             likely to interfere with visual acuity&#xD;
&#xD;
          2. Moderate or severe dry eye as defined by corneal fluorescein staining score of ≥3 on&#xD;
             Oxford scale at Screening&#xD;
&#xD;
          3. Any clinically significant pupillary or iris abnormality (e.g., anisocoria of &gt;1 mm&#xD;
             between eyes at Screening or baseline, abnormal pupil shape in either eye, iris&#xD;
             transillumination defects, or any congenital or traumatic defect of the iris)&#xD;
&#xD;
          4. Narrow iridocorneal angles (Shaffer grade ≤2 or lower on gonioscopy examination),&#xD;
             history of angle-closure glaucoma, or previous iridotomy&#xD;
&#xD;
          5. Intraocular pressure (IOP) &lt;8 mmHg or &gt;23 mmHg in either eye or history of glaucoma or&#xD;
             ocular hypertension&#xD;
&#xD;
          6. Any clinically significant abnormal lens finding (e.g., cataract, loose zonules,&#xD;
             exfoliation, pseudoexfoliation)&#xD;
&#xD;
          7. History of any intraocular surgery including cataract surgery or phakic intraocular&#xD;
             lens surgery&#xD;
&#xD;
          8. History in either eye of previous corneal inlay, full- or partial-thickness corneal&#xD;
             transplant, radial keratotomy or any corneal surgery including laser-based corneal&#xD;
             refractive surgery&#xD;
&#xD;
          9. Any clinically significant abnormal finding on dilated fundus examination in either&#xD;
             eye or known history of retinal detachment, retinal trauma, retinal or vitreal&#xD;
             surgery, or clinically significant retinal disease in either eye&#xD;
&#xD;
         10. Clinically significant strabismus or diplopia&#xD;
&#xD;
         11. History of stereo vision difficulties&#xD;
&#xD;
         12. History of optic neuropathy or amblyopia in either eye&#xD;
&#xD;
         13. Use of orthokeratology contact lenses within the past 1 month prior to EXP039 dosing&#xD;
             on Day 1&#xD;
&#xD;
         14. Use of temporary or permanent punctal plugs or history of punctal cautery in one or&#xD;
             both eyes&#xD;
&#xD;
         15. Planned use of any contact lenses during the study&#xD;
&#xD;
         16. Allergy to pilocarpine or any of its excipients&#xD;
&#xD;
         17. Serious systemic illness that, in the opinion of the Investigator's, would render the&#xD;
             participant ineligible&#xD;
&#xD;
         18. Pre-planned hospitalization or ocular or systemic surgery during the study period&#xD;
&#xD;
         19. History of any substance abuse (alcohol and/or illegal drugs) and not willing to&#xD;
             abstain from drug(s) and reasonably limit alcohol consumption to approximately 2&#xD;
             alcoholic beverages per day during the 30-day study period&#xD;
&#xD;
         20. Participation in any other study of investigational therapy during the study period or&#xD;
             within the last 30 days or 5 half-lives, whichever is longer&#xD;
&#xD;
         21. Unwilling or unable to complete study procedures or to be followed up for the duration&#xD;
             of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milton Hom, OD FAAO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canyon City Eyecare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Canyon City Eyecare</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperopia</keyword>
  <keyword>Myopia</keyword>
  <keyword>Visual Acuity</keyword>
  <keyword>Mesopic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

